Pregabalin, along with extended release lamotrigine and levetiracetam, lacosamide and eslicarbazepine, has recently been shown effective in monotherapy treatment using a historic control design (1). It is helpful to look back at the circuitous history of monotherapy test designs to understand these trials. European authorities accept-and now often require-monotherapy comparator trials of new AEDs approved after successful adjunctive trials (2). Some drugs, such as oxcarbazepine, were compared to up to 4 first-line AEDs in separate trials. The FDA, however, requires objective evidence of monotherapy efficacy rather than comparator trials. Pledger and Kramer (3) developed the inpatient presurgical trial design to safely demonstrate monotherapy efficacy: patients receiving VEEG and tapered off their regular AEDs were randomized either to the new AED (usually at a high dose with rapid titration) or to a placebo or an ineffective low dose of an AED. Time to exit the study was based on seizure recurrence, and proportion of patients completing the brief inpatient study were objective measures of AED efficacy. This design was particularly helpful in evaluating felbamate due to its many drug interactions. In 1999, pregabalin, along with felbamate, oxcarbazepine, and gabapentin, were effective in presurgical monotherapy studies; remacemide was not effective. These trials were criticized by the FDA due to their brief duration; the trials also did not permit slow dose titration, which is necessary for many AEDs (e.g., gabapentin was dosed to 3600 mg in <2 days in a presurgical trial).
Commentary
Pregabalin, along with extended release lamotrigine and levetiracetam, lacosamide and eslicarbazepine, has recently been shown effective in monotherapy treatment using a historic control design (1) . It is helpful to look back at the circuitous history of monotherapy test designs to understand these trials. European authorities accept-and now often require-monotherapy comparator trials of new AEDs approved after successful adjunctive trials (2) . Some drugs, such as oxcarbazepine, were compared to up to 4 first-line AEDs in separate trials. The FDA, however, requires objective evidence of monotherapy efficacy rather than comparator trials. Pledger and Kramer (3) developed the inpatient presurgical trial design to safely demonstrate monotherapy efficacy: patients receiving VEEG and tapered off their regular AEDs were randomized either to the new AED (usually at a high dose with rapid titration) or to a placebo or an ineffective low dose of an AED. Time to exit the study was based on seizure recurrence, and proportion of patients completing the brief inpatient study were objective measures of AED efficacy. This design was particularly helpful in evaluating felbamate due to its many drug interactions. In 1999, pregabalin, along with felbamate, oxcarbazepine, and gabapentin, were effective in presurgical monotherapy studies; remacemide was not effective. These trials were criticized by the FDA due to their brief duration; the trials also did not permit slow dose titration, which is necessary for many AEDs (e.g., gabapentin was dosed to 3600 mg in <2 days in a presurgical trial).
These presurgical inpatient studies were replaced by outpatient studies in which patients converted to monotherapy treatment with either the new AED or a placebo or low dose comparator drug (often the new drug itself ) (4). For safety, these trials used carefully chosen exit criteria with outcomes being a comparison between the randomized groups of the proportion of patients meeting exit criteria and discontinuing blinded treatment. These exit criteria were usually a doubling of the monthly or maximum two-day seizure frequency, new onset of tonic-clonic seizures or investigator judgment that the patient had worsened epilepsy or could not tolerate treatment. These studies, compared to the inpatient presurgical studies, often enrolled patients more typical of those who might try monotherapy: patients with uncontrolled seizures who had failed only several previous AEDs. These studies were criticized as being possibly unethical for randomizing patients to no or ineffective treatment. The majority of OBJECTIVE: To assess pregabalin monotherapy for partial-onset seizures using a historical controlled conversion-tomonotherapy design. METHODS: Adults with inadequately controlled partial-onset seizures while receiving 1 or 2 antiepileptic drugs during an 8-week prospective baseline were randomized to double-blind monotherapy with pregabalin 600 or 150 mg/d (4:1) for 20 weeks (8-week conversion and 12-week monotherapy period). The primary endpoint was the seizure-related exit rate for pregabalin 600 mg/d, based on discontinuations due to predefined criteria. Efficacy was declared if the upper limit of the 95%confidence interval for the exit rate was below a historical-control threshold of 74%, with stepwise evaluation using a threshold of 68%. RESULTS: The trial was stopped early for positive efficacy after an interim analysis in 125 patients. The full study population included 161 patients, with 148 evaluable for efficacy. The mean time since epilepsy diagnosis was 14 years. Overall, 54.3% (600 mg/d) and 46.9% (150 mg/d) of patients completed 20 weeks of double-blind treatment. Seizure-related exit rate in the 600 mg/d group (27.5%; 95% confidence interval, 17.8%-37.2%) was significantly below the 74% and 68% thresholds (p < 0.001 for both). Eight patients on 600 mg/d and 2 on 150 mg/d were seizure-free throughout pregabalin monotherapy. Pregabalin's overall safety profile was consistent with prior trials. CONCLUSIONS: Pregabalin monotherapy was safe and efficacious for patients with inadequately controlled partial-onset seizures. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that patients with inadequately controlled partial-onset seizures switched to pregabalin monotherapy have fewer seizurerelated exit events compared with historical controls switched to pseudo-placebo monotherapy.
Should "Historic Control" Epilepsy Monotherapy Trials Be "History"?
patients (>60%), however, randomized to ineffective treatment met exit criteria rapidly, had benzodiazepine rescue treatments provided, and were then permitted to try open treatment.
Since nearly all of these studies had similar high proportions of control patients exiting the study, it seemed possible that monotherapy efficacy of AEDs could be shown simply by comparing new AEDs to the lower boundary of exit rates defined by the prior controlled monotherapy studies. Jacqueline French (1) and others showed the lower statistical boundary for exiting the "historic controls" was approximately two-thirds; the FDA agreed that AEDs could be approved for a monotherapy indication if they were tested using the same exit criteria, had a lower proportion exiting the trial than historic control patients, and the patients were clinically similar to those in the controlled trials. This pregabalin monotherapy historic control trial is typical (1): after converting to monotherapy treatment with pregabalin 600 mg/day, 27% of patients exited the study; this is markedly lower than the two-thirds exits for the lower boundary of the historic controls. The study did appear to show typical adverse effects of the drug seen in adjunctive trials, that is, 16% had weight gain, though patients discontinuing treatment due to adverse events (including a death) were not included as study exits. The results are consistent with a recent adjunctive pregabalin controlled release study in which treatment with a lower dose of 330 mg/day gave modest effects, not significantly different from a high placebo response in the study, and the response to 165 mg/day and placebo were the same (5) .
Overall, these pregabalin studies point to the confusing effects of regulatory requirements on study designs: the drug was effective in an inpatient monotherapy study in 1999, was effective at several doses in several adjunctive trials, and is now effective when tested in an outpatient conversion to monotherapy study using historic controls. This exhausting path raises the question of whether monotherapy studies are necessary? Monotherapy responses can often be estimated from dose-ranging adjunctive trials: pregabalin 300 mg and 350 mg/day doses gave mixed trial outcomes, while 600 mg was effective in several trials (but with more adverse effects than with lower doses). The greatest benefit of monotherapy trials may be that they permit assessment of high doses of new AEDs without the pharmacokinetic interactions and combined pharmacodynamics effects of the fixed-dose adjunctive "toxicity" trials (this term seems appropriate since typically more than 80% of patients have treatment emergent adverse events in adjunctive AED trials); for example, eslicarbazepine was effective and tolerated at 1200 mg in adjunctive and monotherapy trials and at 1600 mg/day in monotherapy testing (6) . From this perspective, simply permitting controlled reductions of concomitant AEDs during adjunctive trials might improve detection of optimal tolerated doses of new AEDs.
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